Strobeck Matthew
Strobeck Matthew's purchase track record
How the stock did after each of Strobeck Matthew's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/13/2026 | QDEL | $240K | -56.2% | -39.4% | +13.9% |
| 11/5/2024 | BDSX | $56K | -25.4% | -66.6% | -3.0% |
| 11/21/2022 | BDSX | $3.07M | +76.9% | -13.9% | +6.1% |
| 4/7/2022 | BDSX | $2.00M | 0.0% | -16.2% | -16.8% |
| 12/30/2021 | BDSX | $643K | -61.7% | -62.8% | -20.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Biodesix Expands MRD Monitoring Through New Partnerships. Biodesix announced progress in two collaborative programs aimed at tumor‑informed and tumor‑naïve molecular residual disease (MRD) solutions. The company also advanced its MRD monitoring programs by partnering with Bio‑Rad and Thermo Fisher. These developments broaden Biodesix’s portfolio of diagnostic tools for cancer patients.
Transaction History
| QDEL | ▲ Buy | Grant | 6,829 | $0 | 5/29/2026 | View on chart |
| QDEL | ▲ Buy | Open Market | 10,000 | $240K | 2/13/2026 | View on chart |
| QDEL | ▲ Buy | Grant | 4,929 | $0 | 5/22/2025 | View on chart |
| BDSX | ▲ Buy | Open Market | 4,000 | $6K | 11/5/2024 | View on chart |
| BDSX | ▲ Buy | Open Market | 36,000 | $50K | 11/5/2024 | View on chart |
| QDEL | ▲ Buy | Grant | 2,416 | $0 | 5/24/2024 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 52,160 | — | 5/23/2024 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 295,680 | — | 5/23/2024 | View on chart |
| BDSX | ▲ Buy | Grant | 127,777 | $207K | 8/3/2023 | View on chart |
| BDSX | ▲ Buy | Grant | 6,790 | $11K | 8/3/2023 | View on chart |
| BDSX | ▲ Buy | Grant | 6,790 | $11K | 8/3/2023 | View on chart |
| BDSX | ▲ Buy | Grant | 6,790 | $11K | 8/3/2023 | View on chart |
| BDSX | ▲ Buy | Grant | 6,790 | $11K | 8/3/2023 | View on chart |
| BDSX | ▲ Buy | Grant | 140,123 | $227K | 8/3/2023 | View on chart |
| BDSX | ▲ Buy | Grant | 13,580 | $22K | 8/3/2023 | View on chart |
| QDEL | ▲ Buy | Grant | 2,248 | $0 | 6/6/2023 | View on chart |
| QDEL | ▲ Buy | Grant | 427 | $0 | 5/18/2023 | View on chart |
| QDEL | ▲ Buy | Grant | 85 | $0 | 5/18/2023 | View on chart |
| QDEL | ▲ Buy | Grant | 262 | $0 | 5/14/2023 | View on chart |
| QDEL | ▲ Buy | Grant | 875 | $0 | 5/14/2023 | View on chart |
| BDSX | ▲ Buy | Open Market | 869,565 | $1000K | 11/21/2022 | View on chart |
| BDSX | ▲ Buy | Open Market | 108,695 | $125K | 11/21/2022 | View on chart |
| BDSX | ▲ Buy | Open Market | 108,695 | $125K | 11/21/2022 | View on chart |
| BDSX | ▲ Buy | Open Market | 108,695 | $125K | 11/21/2022 | View on chart |
| BDSX | ▲ Buy | Open Market | 108,695 | $125K | 11/21/2022 | View on chart |
| BDSX | ▲ Buy | Open Market | 1,365,217 | $1.6M | 11/21/2022 | View on chart |
| QDEL | ▲ Buy | Grant | 6,533 | — | 5/27/2022 | View on chart |
| QDEL | ▲ Buy | Grant | 38,145 | — | 5/27/2022 | View on chart |
| QDEL | ▲ Buy | Grant | 16,630 | — | 5/27/2022 | View on chart |
| BDSX | ▲ Buy | Open Market | 558,659 | $1000K | 4/7/2022 | View on chart |
| BDSX | ▲ Buy | Open Market | 558,659 | $1000K | 4/7/2022 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 20,044 | — | 3/31/2022 | View on chart |
| BDSX | ▲ Buy | Open Market | 138,700 | $603K | 12/30/2021 | View on chart |
| BDSX | ▲ Buy | Open Market | 9,100 | $40K | 12/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
QuidelOrtho Reports Q2 2026 Results and New IR Lead
QuidelOrtho released its second-quarter 2026 earnings, with reports noting that profit margins have recovered while cash levels remain a point of discussion. The company also announced the appointment of Sanjeev Sharma as Vice President of Investor Relations. These updates provide context for the stock's current position within its 52-week range.
QuidelOrtho Reports Q2 2026 Results and New IR Lead. QuidelOrtho released its second-quarter 2026 earnings, with reports noting that profit margins have recovered while cash levels remain a point of discussion. The company also announced the appointment of Sanjeev Sharma as Vice President of Investor Relations. These updates provide context for the stock's current position within its 52-week range.